To minimize systemic toxic effects associated with traditional anticancer drugs,1 various targeted therapies have been developed to deliver drugs to specific genes or enzymes that promote cancer cell growth in the tumor microenvironment.2,3 Angiogenesis, the formation of new blood vessels, influences cancer growth and metastasis.4 The vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis. This evidence concerns the gene VEGFA and neoplasm.